Frequency and prognostic influence of ASXL1 mutations and its potential association with BCR-ABL1 transcript type and smoke in chronic myeloid leukemia patients

[1]  K. Patel,et al.  Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia , 2022, Blood Cancer Journal.

[2]  T. Brümmendorf,et al.  ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia , 2022, Leukemia.

[3]  Sanaa Nassereddine,et al.  Chronic myeloid leukemia: cytogenetics and molecular biology’s part in the comprehension and management of the pathology and treatment evolution , 2022, Egyptian Journal of Medical Human Genetics.

[4]  S. Sabet,et al.  High Frequency of ASXL1 and IDH Mutations in Young Acute Myeloid Leukemia Egyptian Patients , 2022, Asian Pacific journal of cancer prevention : APJCP.

[5]  S. Mustjoki,et al.  Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia , 2021, Leukemia & lymphoma.

[6]  Xuan Zhou,et al.  Integrative Genomic Analysis Reveals Cancer-Associated Gene Mutations in Chronic Myeloid Leukemia Patients with Resistance or Intolerance to Tyrosine Kinase Inhibitor , 2020, OncoTargets and therapy.

[7]  W. Tapper,et al.  Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking , 2020, Leukemia.

[8]  Mahmoud M. Kamel,et al.  Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. , 2020, Blood advances.

[9]  R. Gale,et al.  Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors , 2019, Haematologica.

[10]  Anna L. Brown,et al.  Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. , 2018, Blood.

[11]  Santosh Kumar,et al.  Benzo(a)pyrene in Cigarette Smoke Enhances HIV-1 Replication through NF-κB Activation via CYP-Mediated Oxidative Stress Pathway , 2018, Scientific Reports.

[12]  Paul P. S. Wang,et al.  ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure. , 2017, Blood advances.

[13]  Marc S. Tyndel,et al.  Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy. , 2017, Leukemia research.

[14]  C. Gambacorti-Passerini,et al.  Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients , 2017, American journal of hematology.

[15]  S. Miyano,et al.  Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia , 2017, Blood cancer journal.

[16]  G. Azizi Tabesh,et al.  ASXL1 and JAK2V617F gene mutation screening in Iranian patients with chronic myeloid leukemia , 2017, Asia-Pacific journal of clinical oncology.

[17]  M. Stratton,et al.  Mutational signatures associated with tobacco smoking in human cancer , 2016, Science.

[18]  S. Holland,et al.  Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation , 2014, Haematologica.

[19]  J. Cigudosa,et al.  ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia , 2013, Blood Cancer Journal.

[20]  Francisco Cervantes,et al.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. , 2013, Blood.

[21]  S. Serrano,et al.  TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms , 2012, Annals of Hematology.

[22]  A. Kohlmann,et al.  A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases , 2011, Leukemia.

[23]  D. Gilliland,et al.  Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms , 2010, Leukemia.

[24]  A. Tefferi,et al.  Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 , 2010, Leukemia.

[25]  R. Kusec,et al.  High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression , 2010, Leukemia.

[26]  N. Cross.  Standardisation of molecular monitoring for chronic myeloid leukaemia. , 2009, Best practice & research. Clinical haematology.

[27]  N. Cross,et al.  Harmonization of molecular monitoring of CML therapy in Europe , 2009, Leukemia.

[28]  Daniel Birnbaum,et al.  Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia , 2009, British journal of haematology.

[29]  M. Yaghmaie,et al.  Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia. , 2008, Archives of Iranian medicine.

[30]  K. Helin,et al.  Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. , 2008, Genes & development.

[31]  Francisco Cervantes,et al.  Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.

[32]  A. Hochhaus,et al.  Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance , 2004, Leukemia.

[33]  C. Creaser,et al.  Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. , 2001, Blood.

[34]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[35]  M. Bienz.  The PHD finger, a nuclear protein-interaction domain. , 2006, Trends in biochemical sciences.

[36]  W. Hiddemann,et al.  Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases , 2002, Leukemia.

[37]  M. Baccarani,et al.  Prognostic discrimination in "good-risk" chronic granulocytic leukemia. , 1984, Blood.